Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5172A versus sofosbuvir + peginterferon/ribavirin in chronic hepatitis C
2014-003836-38Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of elbasvir + grazoprevir, sofosbuvir, peginterferon alfa-2b and ribavirin in chronic hepatitis C (CHC) (2 arms), sponsored by Merck & Co. Primary endpoint: SVR12 rate. Started Nov 2014; status: completed.
02
Drugs
elbasvir + grazoprevirsofosbuvirpeginterferon alfa-2bribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2014-003836-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003836-38.